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INTRODUCTION
Angiogenesis, defined as the formation of new blood vessels 
from pre‑existing vessels, plays crucial roles in many physiological 
processes.[1] During the wound healing process, angiogenesis is 
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The objective of the study was to identify the active fraction(s) from AR aqueous extract responsible for promoting angiogenesis using 
bioassay‑guided fractionation. The angiogenic activity was screened by monitoring the increase of sprout number in sub‑intestinal 
vessel (SIV) of the transgenic zebrafish embryos after they were treated with 0.06‑0.25 mg/ml of AR aqueous extract or its fraction(s) 
for 96 h. Furthermore, the angiogenic effect was evaluated in treated zebrafish embryos by measuring the gene expression of angiogenic 
markers (VEGFA, KDR, and Flt‑1) using real‑time polymerase chain reaction (RT‑PCR), and in human microvascular endothelial 
cell (HMEC‑1) by measuring cell proliferation using 3‑(4,5‑dimethylthiazol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT) assay, 
3H‑thymidine uptake assay, and cell cycle analysis. A major active fraction (P1‑1‑1), which was identified as glycoproteins, was found 
to significantly stimulate sprout formation (2.03 ± 0.27) at 0.125 mg/ml (P < 0.001) and up‑regulate the gene expression of VEGFA, 
KDR, and Flt‑1 by 2.6‑fold to 8.2‑fold. Additionally, 0.031‑0.125 mg/ml of P1‑1‑1 was demonstrated to significantly stimulate cell 
proliferation by increasing cell viability (from 180% to 205%), 3H‑thymidine incorporation (from 126% to 133%) during DNA synthesis, 
and the shift of cell population to S phase of cell cycle. A major AR active fraction consisting of glycoproteins was identified, and 
shown to promote angiogenesis in zebrafish embryos and proliferation of endothelial cells in vitro.
Key words: Astragali Radix, Glycoproteins, Traditional Chinese Medicine, Wound healing
Correspondence to:  
Dr. Clara Bik‑San Lau, Institute of Chinese Medicine, E205, Science Centre East Block, The Chinese University of Hong Kong, Shatin, New Territories, 
Hong Kong SAR, China. Tel: +852‑3943 6109; Fax: +852‑2603 5248; E‑mail: claralau@cuhk.edu.hk
DOI: 10.4103/2225‑4110.139109 
Journal of Traditional and Complementary Medicine Vo1. 4, No. 4, pp. 239‑245
Copyright © 2014 Committee on Chinese Medicine and Pharmacy, Taiwan
involved in proliferation, migration, and differentiation of endo‑
thelial cells with a new basement membrane (Hoeben et al., 2004). 
These promote wound healing process through the delivery of oxy‑
gen and nutrients to the wound site. However, in impaired wound, 
due to poor circulation and reduced oxygenation, angiogenesis 
This is an open access article under the CC BY-NC-ND license.
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will also be affected.[2,3] The resulting chronic wound formed may 
eventually lead to ulceration. One of the examples is diabetic foot 
ulcer.[4,5] If the ulcer is not properly treated, the patient may need 
amputation which may further lead to morbidity and mortality.[6,7]
Astragali Radix (AR), or the root of Astragalus (黃耆 Huáng Qí) 
membranaceus (Fisch.) Bunge (Fabaceae), is a common Chinese 
herb that has been traditionally used in treating various diseases 
such as anemia, fever, wounds, chronic fatigue, uterine bleeding, 
diabetes, and immune‑related diseases.[8,9] It is also one of the 
herbs commonly found in Chinese herbal formulae used for ulcer 
healing.[10] In our previous clinical study, two herbal formulae 
comprising AR as one of the component herbs were shown to res‑
cue 85% of the legs condemned to amputation due to non‑healing 
chronic diabetic ulcer.[11] In addition, AR was shown to be the major 
component in our simplified herbal formula (NF3) which was 
demonstrated to enhance diabetic wound healing in rats through 
tissue regeneration, pro‑angiogenesis, and anti‑inflammation and 
also exhibited pro‑angiogenic effect in zebrafish embryo in vivo 
and rat aortic ring in vitro.[12,13] As a single herb, the research 
focused on its constituents including polysaccharides, triterpene 
saponins, isoflavonoids, and trace elements.[14] In our recent study, 
two major anti‑inflammatory AR active fractions, which may 
enhance wound healing, were identified using bioassay‑guided 
fractionation, and formononetin (an isoflavone) was one of the 
active ingredients in the active fractions (Lai et al., 2013a). Their 
anti‑inflammatory properties were further confirmed by reduc‑
ing the release of inflammatory mediators and inactivation of 
nuclear factor kappa B (NFκB) through mitogen‑activated protein 
kinase (MAPK) signaling pathway (Lai et al., 2013b). In another 
study, AR extract that is enriched in saponin and isoflavone con‑
stituents has been demonstrated to exhibit pro‑angiogenic effect 
in vitro.[15] Calycosin, one of the flavonoids found in AR, induces 
angiogenesis in human umbilical vein endothelial cell (HUVEC) 
and zebrafish embryos.[16] However, other AR angiogenic active 
components might be present, but are not yet identified.
Hence, in this study, we aim to systematically identify active 
fraction(s) from AR which is/are responsible for the pro‑an‑
giogenic effect by bioassay‑guided isolation method in in vivo 
zebrafish model. The isolated fraction(s) will be chemically 
characterized and its angiogenic effects will also be investigated 
in zebrafish model as well as in human microvascular endothelial 
cell (HMEC‑1) model.
MATERIALS AND METHODS
Materials
The raw herb of AR was purchased from mainland China 
and its voucher specimen was deposited in the museum of the 
Institute of Chinese Medicine, The Chinese University of Hong 
Kong, with voucher specimen number 2008‑3201. The procedures 
of authentication and preparation of aqueous crude extract were 
described in our previous publication (Lai et al., 2013a). Extraction 
yield of the crude extract was about 30% (w/w). All chemicals 
and solvents were purchased from Sigma Chemical Company 
(St. Louis, MO, USA) unless otherwise specified. The transgenic 
zebrafish line TG (flil: EGFP) with endothelial cells expressing 
enhanced Green Fluorescent Protein (eGFP) was purchased from 
Zebrafish International Resource Center (University of Oregon, 
USA) and was maintained as described in the previous report.[17] 
The handling of the zebrafish was under the animal licence issued 
and endorsed by Department of Health, the Government of the 
Hong Kong Special Administrative Region and the Animal Experi‑
mentation Ethics Committee of the Chinese University of Hong 
Kong, respectively [reference no.: (09‑530) in DH/HA and P/8/2/1 
Pt. 10]. HMEC‑1 was purchased from the American Type Culture 
Collection (Manassas, VA, USA). The cells were maintained in 
MCDB 131 medium supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Invitrogen, CA, USA), 10 ng/ml epidermal growth 
factor, 1 μg/ml hydrocortisone, penicillin (100 IU/ml), and 
streptomycin (100 μg/ml). They were grown in 37°C humidified 
incubator supplied with 5% CO2.
In vivo zebrafish model
Collection of zebrafish embryos and herbal treatment were per‑
formed as described in our previous report.[18] Briefly, embryos at 
1‑4 cell stage were placed into six‑well plates with 20‑30 embryos 
per well depending on the assay. AR crude extract and its isolated 
fractions were dissolved into embryo medium [19.3 mM NaCl, 
0.23 mM KCl, 0.13 mM MgSO
4
‧7H2O, 0.2 mM Ca (NO3) 2, 1.67 
mM HEPES, pH 7.2] and then filtered. The medium of the wells 
was replaced with the filtered AR extract and fractions in various 
concentrations. After incubation at 28°C for 96 h, sprout forma‑
tion in sub‑intestinal vessel (SIV) region of the treated embryos 
was examined under fluorescence microscope.[16] The number of 
sprouts formed in each embryo was counted.
Bioassay‑guided isolation of active fractions from AR
AR aqueous crude extract was used for the isolation of ac‑
tive fractions by bioassay‑guided fractionation method. For each 
fraction, zebrafish model was applied to evaluate the angiogenic 
activities. The active fractions were selected for further sub‑frac‑
tionation until the most potent fraction(s) or component(s) were 
identified and isolated. Finally, an active fraction P1‑1‑1 was 
identified. A simplified diagram [Figure 1] shows the isolation 
of P1‑1‑1. Firstly, AR aqueous crude extract was re‑dissolved in 
water, and solvent precipitation method using 95% ethanol was 
employed. The resulting precipitate (P1) and supernatant (P2) 
were concentrated under reduced pressure and lyophilized to dry‑
ness. P1 was re‑dissolved in water and further fractionated into 
two sub‑fractions, P1‑1 and P1‑2, by solvent partition method 
using chloroform: n‑butanol (4:1). Among these sub‑fractions, 
P1‑1, which showed the most promising activity [Table 1], was 
selected for further fractionation into five sub‑fractions (P1‑1‑1, 
P1‑1‑2, P1‑1‑3, P1‑1‑4, and P1‑1‑5) by Sephadex G‑100 column. 
According to the result shown in Table 1, P1‑1‑1 showed the 
highest angiogenic activity among these five fractions. Thus, in 
the following experiments, P1‑1‑1 was used to characterize its 
biological activities.
Chemical characterization of active fractions
In order to characterize the chemical property of P1‑1‑1, this 
fraction was further processed to divide into two sub‑fractions, 
P1‑1‑1‑A and P1‑1‑1‑B, as shown in Figure 1. Molecular weight 
241
Lai, et al. / Journal of Traditional and Complementary Medicine 4 (2014) 239‑245
tions were determined by anthrone reagent[19] and bicinchoninic 
acid (BCA) protein assay, respectively.
Quantitation of mRNA expression level of angiogenic 
markers by real‑time polymerase chain reaction
Total RNA was isolated from 20 zebrafish embryos treated 
with or without various concentrations of active fraction (P1‑1‑1) 
for 72 h using NucleoSpin RNA kit (Macherey‑Nagel, Duren, 
Germany). Reverse transcription and polymerase chain reac‑
tion (PCR) amplification were carried out using iScript One‑Step 
real‑time polymerase chain reaction (RT‑PCR) kit supplied 
by Bio‑Rad (CA, USA). The reaction mixture contained 15 μl 
of RT‑PCR reagent mix, 3 μl of 10 mM primer mix of target 
gene (VEGFA, Flt‑1, or KDR) or house‑keeping gene (β‑actin), 
0.2 μl of reverse transcriptase, 5 μl of RNA template, and 11.8 μl 
of nuclease‑free water. Their primer sequences are as follows: 
VEGFA, 5′‑TCCAGGAGTATCCCGATGAG‑3′ and 5′‑GCTTT‑
GACTTCTGCCTTTGG‑3′; Flt‑1, 5′‑ATGGGAACAGCAG‑
CACTCTT‑3′ and 5′‑TTGAAGACGGAGGGACAATC‑3′; KDR, 
5′‑TGTGGTCAGCTATGCTGGAG‑3′ and 5′‑AGCCTCTCAT‑
GCTGTGGACT‑3′; β‑actin, 5′‑CTCTTCCAGCCTTCCTTCCT‑3′ 
and 5′‑CTTCTGCATACGGTCAGCAA‑3’. RT‑PCR was then 
performed by CFX96 Real‑Time System (Bio‑Rad, CA, USA). 
Analysis of expression of VEGFA, Flt‑1, and KDR was preformed 
using β‑actin as the control gene for normalization.
Measurement of cell viability by MTT assay
Cell viability was determined by 3‑(4,5‑dimethylthi‑
azol‑2‑yl)‑2,5‑diphenyltetrazolium bromide (MTT) assay. 
HMEC‑1 cells (5 × 103 cells/well) were seeded in 96‑well culture 
plates and incubated overnight for attachment. Then, the cells were 
arrested with 0.5% (v/v) FBS in MCDB 131 medium for another 
24 h. After further treating them with various concentrations of 
P1‑1‑1 for 24 or 48 h, the culture medium was removed and 40 μl 
of MTT solution [5 mg/ml in phosphate‑buffered saline (PBS)] was 
added to each well. After incubation for 3 h at 37°C, MTT solution 
was removed and 100 μl of dimethyl sulfoxide was added to dis‑
solve the crystals formed. Then, absorbance at 540 nm was mea‑
Table 1. Summary of the angiogenic effects of AR crude extract and 
isolated fractions on in vivo zebrafish model
Fraction Most effective 
concentration (mg/ml)
No. of sprouts per 
embryo (mean±SEM)
Yield 
(% w/w)
Crude 0.25 1.78±0.21*** 30.0 
P1 0.25 1.83±0.37*** 3.6
P2 0.25 0.95±0.18*** 26.4
P1‑1 0.25 2.46±0.24*** 0.4
P1‑2 0.125 0.98±0.17*** 3.2
P1‑1‑1 0.125 2.03±0.27*** 0.072
P1‑1‑2 0.0625 0.23±0.08 0.084
P1‑1‑3 0.0625 0.20±0.12 0.03
P1‑1‑4 0.0625 0.30±0.10 0.017
P1‑1‑5 0.125 0.12±0.06 0.018
Control ‑ 0.10±0.01 ‑
Data are expressed as number of sprouts per embryo (mean±SEM) of 
not less than three independent experiments (total embryo number ≥60). 
Extraction yield was expressed as weight percentage of original raw herb. 
***P<0.001 when compared to the control using one‑way ANOVA with 
Dunnett’s multiple comparison test
Figure 1. Schematic diagram showing the method for bioassay‑guided fractionation of AR aqueous crude extract and representative images of zebrafish 
study. (a) Active fractions at each level (shown in gray boxes) were selected for further fractionation. P1‑1‑1 was the fraction finally selected for mechanistic 
study. (b) Zebrafish embryos treated with (i) embryo medium only and zebrafish embryos treated with P1‑1‑1 at (ii) 0.03125 mg/ml, (iii) 0.0625 mg/ml, 
and (iv) 0.125 mg/ml. Red arrows indicate the smooth basket‑like structure of sub‑intestinal vessel (SIV) appearing at the bottom of each embryo. Yellow 
arrows indicate the new blood vessels (sprouts) formed on the SIV of embryos treated with P1‑1‑1 which were observed in (iii) and (iv)
ba
distribution of the three isolated active fractions (P1‑1‑1, P1‑1‑1‑A, 
and P1‑1‑1‑B) was determined by gel filtration chromatogra‑
phy (GFC) using Waters (Milford, MA, USA) ACQUITY ultra per‑
formance liquid chromatograph (UPLC) equipped with a calibrated 
7.8 mm × 30 cm, 7 μm TSKgel G3000 column (Tosoh Bioscience, 
Tokyo, Japan) and evaporative light scattering detector (Alltech, 
Columbia, USA). The column was equilibrated with water at a 
flow rate of 0.5 ml/min. The molecular mass range of dextran 
standards (Fluka, Buches, Switzerland) used for calibration was 
5‑2000 kDa. The retention times plotted as a function of the 
logarithm of molecular mass and the respective linear regression 
obtained were used for molecular mass determination. Sodium do‑
decyl sulfate polyacrylamide gel electrophoresis (SDS‑PAGE) was 
performed with the fractions (10 mg/ml) using 10% (w/v) acryl‑
amide in gels. The reference markers used were the high‑range 
rainbow markers (GE Healthcare, Buckinghamshire, UK). Gly‑
coprotein was detected by the periodic acid‑Schiff (PAS) staining 
of the gel.[14] The carbohydrate and protein content in the frac‑
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sured using a microplate reader. The percentage cell viability was 
calculated as [Absorbance
 (treatment)
/Absorbance
 (negative control)
] ×100%.
Measurement of DNA synthesis by 3H‑thymidine uptake 
assay
HMEC‑1 cells (5 × 103 cells/well) were seeded in 96‑well 
culture plates and incubated overnight for attachment. Then, the 
cells were arrested with 0.5% (v/v) FBS in MCDB 131 medium 
for another 24 h. After further treating them with various con‑
centrations of P1‑1‑1 for 24 or 48 h, 0.5 μCi of 3H‑thymidine in 
PBS (Invitrogen, USA) was added to each well and the cells were 
incubated at 37°C for 6 h. Then, DNA was harvested on micro‑
filters with a cell harvester (Beckman Coulter, Brea, CA, USA). 
The amount of DNA synthesized was determined by measuring 
the radioactivity of the filter using a microplate scintillation coun‑
ter (Beckman Coulter).
Cell cycle analysis
HMEC‑1 cells (3 × 105 cells/well) were seeded into six‑well 
culture plates and incubated overnight for attachment. After 
synchronization with 0.5% FBS in MCDB 131 medium for 24 h, 
the cells were treated with various concentrations of P1‑1‑1 or 
vehicle for a further 24 or 48 h. Then, the cells were harvested and 
fixed in 70% ethanol. Before performing flow cytometry, ethanol 
was removed and the cells were incubated with RNase (8 μg/ml) 
and propidium iodide (10 μg/ml) for 30 min. Cell cycle distribu‑
tion was then detected using a flow cytometer (BD FACSCanto, 
BD  BioSciences, CA, USA), and the results were analyzed using 
ModfitLT version 3.0 software.
Statistical analysis
All experiments were performed in not less than three replicates 
and the results were presented as mean ± standard deviation (SD) 
for in vitro studies or mean ± standard error of the mean (SEM) 
for in vivo studies. One‑way analysis of variance (ANOVA) with 
Dunnett’s multiple comparison test was used for comparisons 
among various treatment groups and the control group. Results 
were considered statistically significant when P < 0.05.
RESULTS AND DISCUSSION
Angiogenic effects of AR crude extract and its fractions
In the present study, we identified the major angiogenic 
active fraction that possibly contributed to the wound healing 
property of AR by bioassay‑guided fractionation [Figure 1a] 
using zebrafish embryo in vivo model. As shown in Table 1, 
AR crude extract at 0.25 mg/ml was demonstrated to en‑
hance angiogenesis significantly by the increased number of 
sprouts (1.78 ± 0.21) formed in treated embryos when com‑
pared with control (0.10 ± 0.01, P < 0.001). Two downstream 
fractions, P1 (macromolecules) and P2 (small molecules) 
separated by ethanol precipitation method, were also found to 
have significant activities at 0.25 mg/ml and, thus, fraction‑
ation was conducted on both fractions. Among seven resulting 
sub‑fractions tested, P1‑1 showed the most promising angio‑
genic effect (2.46 ± 0.24) and, therefore, was further fractionated 
into five sub‑fractions (P1‑1‑1 to P1‑1‑5) by Sephadex G‑100 
column. P1‑1‑1 was selected as it showed the highest enhancing 
effect (2.03 ± 0.27) among the five fractions tested. When com‑
paring to the mother fraction (P1‑1), the effective concentration 
of P1‑1‑1 was lower (0.125 mg/ml). When P1‑1‑1 was further 
fractionated into P1‑1‑1‑A and P1‑1‑1‑B, it was found that the 
activities of these sub‑fractions were decreased. Therefore, 
P1‑1‑1 was identified as the major active angiogenic fraction 
of AR. Zebrafish (Danio rerio) embryos were chosen as in vivo 
model for discovery of bioactive drugs from natural sources due 
to their high genetic similarity to human, high reproducibility, 
and short generation time, ease of drug administration, as well 
as their optical transparency for allowing visualization of drug 
effects on internal organs and tissues.[20] Additionally, transgenic 
zebrafish with florescent blood vessels have been extensively 
used for study of embryonic blood vessel formation in the area 
of angiogenesis since they offer a less labor‑intensive method 
of visualizing blood vessels in the zebrafish embryo.[21]
Chemical characterization of major active fraction P1‑1‑1
P1‑1‑1 was isolated from P1 which was composed of 
macromolecules. The chemical property of P1‑1‑1 has been 
characterized in terms of P1‑1‑1‑A and P1‑1‑1‑B. The results 
of GFC [Figure 2] showed that three groups of macromol‑
ecules (P1‑1‑1‑A1, P1‑1‑1‑B1, and P1‑1‑1‑B2) were present 
in P1‑1‑1, and their molecular weights were estimated to be 
229‑2396 kDa, 5.3‑143 kDa, and 1.6 kDa, respectively, with 
P1‑1‑1‑A1 originating from the sub‑fraction P1‑1‑1‑A and the 
others from P1‑1‑1‑B [Table 2]. Additionally, when P1‑1‑1 was 
analyzed by SDS‑PAGE, a broad band of large molecular size 
(>76 kDa) and a band of small molecular size (about 38 kDa) 
were observed [Figure S1, Supplementary Information]. When 
compared with the results of GFC, these two bands were iden‑
tified as P1‑1‑1‑A1 and P1‑1‑1‑B1, respectively [Table 2]. 
It was suggested by PAS staining that the fractions were 
glycoproteins [Figure S1, Supplementary Information]. The 
carbohydrate content of the fractions was analyzed and the 
results are summarized in Table 2. They were estimated to 
Figure 2.  Gel filtration chromatogram (GFC) of the major active fraction 
P1‑1‑1 and its sub‑fractions (P1‑1‑1‑A and P1‑1‑1‑B). P1‑1‑1‑A1, P1‑1‑
1‑B1, and P1‑1‑1‑B2 were three groups of macromolecules identified in 
P1‑1‑1 by GFC
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average number of sprouts formed per embryo was significantly 
increased from 0.76 to 2.03 (P < 0.001) after treating the embryos 
with 0.0625 mg/ml and 0.125 mg/ml of P1‑1‑1 and the stimulation 
was in a concentration‑dependent manner [Figure 3a]. The repre‑
sentative pictures of P1‑1‑1 treated zebrafish embryo and control 
embryo are shown in Figure 1b. In order to identify the molecular 
targets of the angiogenic effects of P1‑1‑1 in zebrafish embryos, 
RT‑PCR was used to quantify the mRNA expression levels of se‑
lected genes involved in vascular endothelial growth factor (VEGF) 
contain 45.1‑70.6% (w/w) of carbohydrate and 11.7‑15.9% 
(w/w) of protein.
P1‑1‑1 stimulated sprout formation in zebrafish embryos by 
up‑regulating expression of angiogenic markers
The angiogenic activity and underlying mechanism of P1‑1‑1 
was further evaluated using zebrafish model. Results indicated the 
Figure 3. Effects of P1‑1‑1 on sprout formation and mRNA expression of three angiogenic markers (Flt‑1, KDR, VEGFA) in zebrafish embryos. (a) Sprout 
formation was expressed as number of sprouts per embryo (mean ± SEM) of not less than three independent experiments. For (b) Flt‑1, (c) KDR, and 
(d) VEGFA, the expression levels were normalized and expressed as mean ± SEM of not less than three independent experiments. *P < 0.05, **P < 0.01, 
and ***P < 0.001 indicate significant difference when compared to control using one‑way ANOVA with Dunnett’s multiple comparison test
dc
ba
Figure S1. SDS‑PAGE analysis of angiogenic active fraction (P1‑1‑1) and 
its sub‑fractions (P1‑1‑1‑A and P1‑1‑1‑B). The resulting gel was further 
stained with PAS. The bands (P1‑1‑1‑A1 and P1‑1‑1‑B1) in the lanes of 
P1‑1‑1, P1‑1‑1‑A and P1‑1‑1‑B were stained positively with PAS
Table 2. Chemical characterization of P1‑1‑1, P1‑1‑1‑A, and P1‑1‑1‑B
Test item P1‑1‑1 P1‑1‑1‑A P1‑1‑1‑B
Molecular weight 
distribution by 
gel filtration 
chromatography (kDa)
P1‑1‑1‑A1 
(229‑2396)
P1‑1‑1‑B1 (5.3‑143) 
P1‑1‑1‑B2 (~1.6)
P1‑1‑1‑A1 
(366‑1894)
P1‑1‑1‑B1 
(3.3‑89) 
P1‑1‑1‑B2 
(~1.4)
Molecular weight by 
SDS‑PAGE (kDa)
P1‑1‑1‑A1 (>76)
P1‑1‑1‑B1 (~38)
P1‑1‑1‑A1 
(>76)
P1‑1‑1‑B1 
(~38)
SDS‑PAGE stained 
with PAS (tested for 
glycoprotein)
Positive Positive Positive
Carbohydrate 
content (%w/w)
45.1 70.6 48.5
Protein content (%w/w) 11.7 15.9 15.3
Carbohydrate and protein content were determined by anthrone reagent and 
BCA protein assay, respectively. BCA: Bicinchoninic acid; SDS‑PAGE: Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis; PAS: Periodic acid‑Schiff 
staining for glycoprotein
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signaling pathway. VEGF and its tyrosine kinase receptors 
(VEGFRs) are the key regulators in angiogenesis and are highly 
specific to endothelial cells.[22] VEGFA, the most important member 
of VEGF, binds and activates the two VEGFRs, VEGFR‑1 (Flt‑1) 
and VEGFR‑2 (KDR), subsequently initiates the main signaling 
pathway.[23,24] As shown in Figure 3b‑d, 0.125 mg/ml of P1‑1‑1 was 
demonstrated to significantly up‑regulate mRNA expression of 
these regulators, 5.7‑fold for Flt‑1, 2.6‑fold for KDR, and 8.2‑fold 
for VEGFA (P < 0.05). Therefore, our results suggested that the 
angiogenic effect of P1‑1‑1 observed in zebrafish embryos was at 
least partly mediated via VEGF signaling pathways.
P1‑1‑1 stimulated HMEC‑1 cell viability, DNA synthesis and 
cell population in S phase
Proliferation of endothelial cells is the first and the primary 
event in angiogenesis. Therefore, HMEC‑1 were used to examine 
the angiogenic effects of P1‑1‑1 by measuring cell proliferation us‑
ing MTT assay, 3H‑thymidine uptake assay, and cell cycle analysis. 
After the cells were incubated with P1‑1‑1 at a concentration range 
of 0.03125‑0.125 mg/ml for 24 or 48 h, increased cell viability was 
observed in MTT assay when compared to the control which was 
set to 100% (P < 0.001) [Figure 4a and b]. In a similar manner, 
P1‑1‑1 also significantly accelerated the uptake of 3H‑thymidine 
under the same concentration range (P < 0.01) [Figure 4c and d]. 
The results indicated that cellular DNA synthesis was enhanced 
by P1‑1‑1. This was further verified by the increased S (synthesis) 
phase population in cell cycle analysis. As shown in Table 3, P1‑1‑1 
at concentrations of 0.0625 mg/ml and 0.125 mg/ml significantly 
increased the cell population in S phase after 24 h (from 27.4 to 
32.7%) and 48 h (from 20.7 to 26.0%) incubation (P < 0.05).
Previous in vitro and in vivo studies of AR extract and its 
constituents (calycosin, astragaloside IV, and polysaccharides) 
have confirmed their pro‑angiogenic activities.[15,16] However, 
very few biological studies of its glycoprotein were found, except 
a pathogenesis‑related class 10 protein (PR‑10), a glycoprotein 
isolated from AR, which was shown to exhibit ribonuclease ac‑
tivity.[14] It was found that the isolated AR active fraction P1‑1‑1, 
Table 3. Effects of P1‑1‑1 on cell cycle distribution of HMEC‑1 cells
Incubation 
time (h)
P1‑1‑1 
(mg/ml)
Cell population (%)
G0/G1 S G2/M
24 0 51.5±2.0 27.4±1.7 21.1±1.1
0.03125 49.7±2.3 30.6±3.5 19.8±1.9
0.0625 47.3±0.7 32.1±1.9* 20.6±1.8
0.125 46.1±2.1* 32.7±1.6* 21.2±1.3
48 0 60.1±3.9 20.7±1.9 19.2±2.0
0.03125 58.2±1.5 23.7±0.8 18.1±1.2
0.0625 57.2±0.5 24.9±2.2* 17.9±1.8
0.125 56.2±1.0 26.0±0.7** 17.8±1.2
Data were expressed as percentage of cell population (mean±SD) of three 
independent experiments. *P<0.05 and **P<0.01 when compared to the 
control using one‑way ANOVA with Dunnett’s multiple comparison test
Figure 4. Effect of P1‑1‑1 on HMEC‑1 cell viability and DNA synthesis. The cells were treated with P1‑1‑1 (0.03125‑0.125 mg/ml). (a, b) MTT 
assay and (c, d) 3H‑thymidine uptake assay were performed after 24 and 48 h. Data were expressed as mean ± SD of not less than three independent 
experiments. **P < 0.01 and **P < 0.001 indicate significant difference when compared to control using one‑way ANOVA with Dunnett’s multiple 
comparison test
dc
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which consisted of glycoproteins, stimulated angiogenesis in 
zebrafish embryos via up‑regulated expression of VEGF and 
its tyrosine kinase receptors, and proliferation of HMEC‑1 cells 
by increasing cell viability, DNA synthesis and the shift of cell 
population to S phase of cell cycle in which DNA replication was 
stimulated. Taken together, it was suggested that P1‑1‑1 was a 
glycoprotein‑containing active fraction which partially contributed 
to the angiogenic activity of AR.
The analysis of gene expression of VEGFA, KDR, and Flt 
in HMECs, as well as cell migration and differentiation will be 
included in our future study.
CONCLUSION
In the present work is presented the isolation of an angiogenic 
active fraction of AR by bioassay‑guided fractionation using 
in vivo model. The fraction comprising glycoproteins exhibited 
angiogenic activity in zebrafish embryos via VEGF signaling 
pathway, and stimulated the proliferation of HMEC‑1 cells by 
increasing cell viability and DNA synthesis.
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